{"version":"1.0","type":"link","title":"Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.","author_name":"Orlov SV 외","author_url":"https://prs-insight.online/author/Orlov%20SV","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94055","thumbnail_width":1200,"thumbnail_height":630}